Fixed-Dose Tavapadon for Early Parkinson Disease

Can treatment with tavapadon, an oral, once-daily, selective D1/D5 agonist, safely improve motor control for people with early Parkinson disease (<3 years’ disease duration)?In this phase 3, double-blind, placebo-controlled, 27-week randomized clinical trial of 529 participants with early Parkinson disease, treatment with fixed daily doses of tavapadon (5 or 15 mg) resulted in significant improvements in Movement Disorder Society–Unified Parkinson’s Disease Rating Scale parts II and III combined scores at week 26 relative to placebo. Most adverse events were mild to moderate in severity; the most common adverse events in the tavapadon group were nausea, headache, and dizziness.Tavapadon provided statistically significant and clinically meaningful improvements in motor function with an acceptable safety profile in adults with early Parkinson disease.

Corresponding Author: Angelo Antonini, MD, PhD, Padova Neuroscience Center, Via Giuseppe Orus 2, 35131 Padova, Italy (angelo.antonini@unipd.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.